Next-Gen SERD Cuts Breast Cancer Recurrence Risk by 30% in Trial

(MedPage Today) -- SAN ANTONIO--In a large phase III trial of adjuvant treatment for early-stage breast cancer, the investigational oral drug giredestrant reduced the risk of invasive disease recurrence by 30% versus standard endocrine therapy...